# Eureka Therapeutics

Source: https://onco.cc/companies/eureka-therapeutics/  
OnCo record `eureka-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Eureka Therapeutics is a US-based cell therapy company that leads 2 cancer trials in OnCo, testing the ARTEMIS T-cell therapies ECT204 and ET140203 in hepatoblastoma and hepatocellular carcinoma.

## Summary

Eureka Therapeutics is a clinical-stage biopharmaceutical company developing T-cell therapies for solid tumours using its E-ALPHA antibody discovery and ARTEMIS T-cell receptor platforms. Its clinical programmes are ECT204 for GPC3-positive adult liver cancer and ET140203 for AFP-positive paediatric liver cancer. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT04634357 (phase 1/2, ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular...) and NCT04864054 (phase 1/2, GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Eureka Therapeutics Inc.
- Tags: ctgov-sponsor
- HQ: Emeryville, California
- Type: cell-therapy
- Website: https://www.eurekatherapeutics.com

## Sources

- Official website: https://www.eurekatherapeutics.com
- ClinicalTrials.gov: trials led by Eureka Therapeutics: https://clinicaltrials.gov/search?lead=Eureka%20Therapeutics%20Inc.

## Connected records

- cancers: [Hepatoblastoma](https://onco.cc/cancers/hepatoblastoma/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- trials: [ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma](https://onco.cc/trials/nct04634357/), [GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC](https://onco.cc/trials/nct04864054/)

---
JSON: https://onco.cc/api/v1/entities/eureka-therapeutics.json